Skip to main content

Table 1 Demographics, clinical characteristics and BAL cell yields for bronchoscopy subjects

From: Anti-inflammatory potential of PI3Kδ and JAK inhibitors in asthma patients

  Healthy Asthma
Number 21 25
Sex (m/f) 10/11 13/12*
Age 38.5+/− 13.1 43.8 +/−12.0*
Age of asthma diagnosis N/A 16.1 +/−16.0
Body Mass Index 25.7 +/− 3.5 27.3 +/− 3.3*
Atopy (Y/N) 1/20 21/4a
ACQ score N/A 1.85 +/− 0.79
FEV1 % predicted 103.7+/−17.2 72.4 +/− 15.5***
FEV1/FVC 78.8 +/−5.4 65.8 +/− 10.4***
Reversibility (%) 3.2 +/− 2.6 18.9 +/− 17.4**
SABA (y/n) 0/21 24/1a
LABA (y/n) 0/21 21/4a
ICS (y/n) 0/21 25/0**
Beclomethasone dose (μg/day) 0 1125+/− 558
BAL cell yields (×106/ml BAL) 0.099 +/− 0.038 0.107 +/−0.072*
  1. Data is presented as mean +/− standard deviation. Comparisons between groups were by T-test: *p > 0.05; **p < 0.01; ***p < 0.001, or by Chi-square test: a p < 0.001
  2. Abbreviations: ACQ asthma control questionnaire, FEV 1 Forced expiratory volume in one second, FVC forced vital capacity, SABA short acting β-agonist, LABA long acting β-agonist, ICS inhaled corticosteroid; N/A not applicable